2026-06-28T20:26:18Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1148582025-01-18T00:58:42Zcom_20.500.14352_14col_20.500.14352_15

Supplementation with hydroxytyrosol and punicalagin improves early atherosclerosis markers involved in the asymptomatic phase of atherosclerosis in the adult population: A randomized, placebo-controlled, crossover trial Quirós-Fernández, Rebeca López Plaza, Bricia Bermejo López, Laura María Palma-Milla, Samara Gómez-Candela, Carmen Hydroxytyrosol (HT) and Punicalagin (PC) exert cardioprotective and anti-atherosclerotic effects. This study evaluates the effect of oral supplementation with HT and PC (SAx) on early atherosclerosis markers in middle-aged, seemingly healthy adults. A randomized, double-blinded, placebo-controlled, crossover trial was performed for 20 weeks. There were two treatment sequences (Placebo/SAx, n = 41; SAx/Placebo, n = 43) for which the intervention periods (Placebo and SAx) were 8 weeks long, followed by a 4-week wash out period. The supplement was composed of 9.9 mg of HT and 195 mg of PC, and the placebo was composed of maltodextrin. SAx increased endothelial function (Flow-mediated dilatation [FMD]: 2.36%; p < 0.001) in the endothelial dysfunction subgroup compared to the placebo (2.36 ± 3.9 vs. 0.76 ± 3.5%, p < 0.05). SAx also reduced oxLDL by -28.74 ng/mL (p < 0.05) in subjects with higher levels of oxLDL, which was an improvement compared with the placebo (-28.74 ± 40.2 vs. 25.64 ± 93.8 ng/mL, p < 0.001). The prehypertension and hypertension subgroups exhibited decreased systolic (-15.75 ± 9.9 mmHg; p < 0.001) and diastolic (-6.36 ± 8.7 mmHg; p < 0.001) blood pressure after SAx consumption. Moreover, the systolic prehypertension and hypertension subgroups presented significant differences in systolic blood pressure compared to the placebo (-15.75 ± 9.9 vs. -2.67 ± 12.0 mmHg, p < 0.05). In conclusion, the supplement exerted anti-atherosclerotic effects by improving endothelial function, blood pressure, and levels of circulating oxLDL, especially for persons in whom these parameters were altered. 2025-01-17T09:26:56Z 2025-01-17T09:26:56Z 2019-03-01 journal article Quirós-Fernández R, López-Plaza B, Bermejo LM, Palma-Milla S, Gómez-Candela C. Supplementation with Hydroxytyrosol and Punicalagin Improves Early Atherosclerosis Markers Involved in the Asymptomatic Phase of Atherosclerosis in the Adult Population: A Randomized, Placebo-Controlled, Crossover Trial. Nutrients. 2019 Mar 16;11(3):640. 10.3390/NU11030640 https://hdl.handle.net/20.500.14352/114858 2072-6643 https://doi.org/10.3390/nu11030640 https://pubmed.ncbi.nlm.nih.gov/30884808/ https://pmc.ncbi.nlm.nih.gov/articles/PMC6470561/ eng info:eu-repo/grantAgreement/MICINN//CEN-20101016/ES/DESARROLLO DE NUEVAS METODOLOGÍAS Y TECNOLOGÍAS EMERGENTES PARA LA EVIDENCIACIÓN DE ALIMENTOS CON PROPIEDADES DE SALUD PARA LA REDUCCIÓN DE RIESGO DE PATOLOGÍAS CRÓNICAS DESDE LA EDAD MEDIA DE VIDA/ open access MDPI